Opioid Agonist Therapy
A new guideline recommends opioid agonist therapy with buprenorphine-naloxone as first-line for the treatment of opioid use disorder.
Slow-Release Oral Morphine, a Promising Opioid Agonist Therapy Alternative to Buprenorphine, MethadoneJanuary 11, 2018
Slow-release oral morphine may be a valuable tool to help reduce the number of deaths from opioid-related overdose.
Immediate access to opioid agonist treatment for patients presenting with opioid use disorder may provide greater health benefits at less cost than observed standard of care.
A small fraction of prescriptions for Medicare patients are for opioid agonist therapy, despite higher rates of abuse.
Clinical Pain Advisor Articles
- Risks Associated With Co-Administration of Aspirin and Other NSAIDs
- Stages of Low Back Pain Have Specific Sets of Clinical Indicators
- FDA Approves Aimovig for Migraine Prevention
- First Non-Opioid Drug Approved for Managing Opioid Withdrawal Symptoms
- Pain Interference Associated With Depression, Pain Self-Efficacy in Chronic Musculoskeletal Pain
- Effect of Prescription Drug Monitoring Programs on Fatal, Nonfatal Drug Overdoses
- Standardized SCS Workflow May Effectively Alleviate Failed Back Surgery Syndrome-Related Pain
- Marijuana Legalization and Opioid Prescribing Rates
- Medical Marijuana Users More Likely to Use Prescription Drugs for Medical, Nonmedical Purposes
- Interbrain Coupling During Handholding Associated With Analgesia, Empathy
- Remission Rates and Predictors of Chronic Headache
- Overuse and Underuse of Imaging Common in Low Back Pain Management
- Unit-Dose Packaging of Buprenorphine-Naloxone Effective on Unintentional Pediatric Exposure
- Language Used in Medical Record Can Affect Patient Care
- Opioid-Related Adverse Drug Events Associated With Worse Patient, Cost Outcomes